The groovy C4T Office

As we continue our in-depth post AACR21 coverage, it’s time for part two in the protein degradation series with a look at C4 Therapeutics and what we can learn from their preclinical data presentation of CFT7455, where they aim to¬†selectively destroy disease-causing proteins in multiple myeloma and lymphomas through degradation of IKZF1/3.

Also included is the second half of an interview with their charismatic CSO, Dr Stew Fisher where we discuss degraders, glues, IMiDs and CELMoDs…

To learn more about our ongoing post AACR21 meeting analysis and expert interviews to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by